key: cord-0945243-tfqd493v
authors: Gatti, Milo; Andreoni, Massimo; Pea, Federico; Viale, Pierluigi
title: Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs
date: 2021-08-03
journal: Drug Des Devel Ther
DOI: 10.2147/dddt.s313756
sha: 01778b305b703492bf79a640b93eb461bd632c90
doc_id: 945243
cord_uid: tfqd493v

Dalbavancin is a novel, long-acting lipoglycopeptide characterized by a long elimination half-life coupled with excellent in vitro activity against multidrug-resistant Gram-positives. Although it is currently approved only for the treatment of acute bacterial skin and skin structure infections, an ever-growing amount of evidence supports the efficacy of dalbavancin as a long-term therapy in osteomyelitis, prosthetic joint infections, endocarditis, and bloodstream infections. This article provides a critical reappraisal of real-world use of dalbavancin for off-label indications. A search strategy using specific keywords (dalbavancin, osteomyelitis, endocarditis, long-term suppressive therapy, bloodstream infection, pharmacokinetic/pharmacodynamic profile) until April 2021 was performed on the PubMed-MEDLINE database. As for other novel antibiotics, a conundrum between approved indications and potential innovative therapeutic uses has emerged for dalbavancin as well. The promising efficacy in challenging scenarios (i.e., osteomyelitis, endocarditis, prosthetic joint infections), coupled with the unique pharmacokinetic/pharmacodynamic properties, makes dalbavancin a valuable alternative to daily in-hospital intravenous or outpatient antimicrobial regimens in the treatment of long-term Gram-positive infections. This makes dalbavancin valuable in the current COVID-19 scenario, in which hospitalization and territorial medicine empowerment are unavoidable.

Dalbavancin is a novel, long-acting lipoglycopeptide active against Gram-positive pathogens, including multi-drug resistant isolates. 1 Long elimination half-life and good tissue penetration represent the main pharmacokinetic features of dalbavancin, 2 allowing for long-term efficacy despite the simplified weekly administration regimens. It was approved by the US Food and Drug Administration and the European Medicines Agency in 2014 and 2015 for the management of acute bacterial skin and skin structure infections (ABSSSIs) on an intravenous dosing regimen of 1500 mg as a single infusion or 1000 mg followed by 500 mg one week apart. 3, 4 Currently, ABSSSIs remain the only approved indication for dalbavancin, although this could represent a non-innovative and inefficient exploitation of its pharmacokinetic/pharmacodynamic (PK/PD) properties. Indeed, as reported for other novel antibiotics (e.g., ceftazidime-avibactam), 5 a conundrum between approved indications and potential innovative therapeutic uses has emerged for dalbavancin. 6 An ever-growing amount of evidence supports the efficacy of dalbavancin as a long-term therapy for off-label indications, namely osteomyelitis, prosthetic joint infections, endocarditis, and bloodstream infections, [6] [7] [8] in which a treatment for at least 6 weeks is usually required. 9, 10 In the current COVID-19 era, patients requiring prolonged antibiotic therapy after hospital discharge due to severe bacterial infections (e.g., endocarditis or osteomyelitis) are at increased risk for contracting and/or transmitting COVID-19 due to extensive contact with the healthcare system. 11 By virtue of its PK/PD properties, dalbavancin could be a valuable alternative to daily in-hospital intravenous or outpatient antimicrobial regimens in the treatment of long-term Gram-positive infections, providing an added value in the current COVID-19 scenario, in which ineluctable hospitalization and empowerment of territorial medicine are strongly required. We performed a critical reappraisal of real-world use of dalbavancin for off-label indications, suggesting therapeutic algorithms according to different clinical scenarios.

A literature search was conducted on PubMed-MEDLINE (from inception until April 2021) in order to retrieve randomized controlled trials (RCTs), prospective or retrospective observational studies, case series, and case reports investigating the use of dalbavancin for off-label indications. Six different main topics focusing on innovative use of dalbavancin were identified by three experts in the field (PV, MA, and FP), namely PK/PD properties, osteomyelitis, endocarditis and bloodstream infections, long-term suppressive therapy, safety, and quality of life. The following terms were searched on PubMed in combination: dalbavancin, endocarditis, bloodstream infection, osteomyelitis, bone, prosthetic joint, long-term, off-label indication, pharmacokinetic, PK/PD, safety, quality of life.

Only studies in which clinical outcome associated with dalbavancin use was reported for each off-label indication were included. Articles were excluded if: only cumulative efficacy of dalbavancin for different off-label indications was provided; different long-acting lipoglycopeptides were investigated and clinical outcome for each single agent was not provided. There were no language restrictions. For each included study, the following information was extracted: (a) study author and year of publication; (b) study characteristics including study design and sample size; (c) features of the patients including site of infection, proportion of prior antibiotic therapy and duration, dalbavancin dosing schedule, isolated pathogens, and duration of follow-up; (d) types of outcome measurements, including rate of clinical success or improvement, clinical and/or microbiological failure rate, mortality rate, relapse rate, resistance development, and overall proportion of adverse events. Cumulative incidence of the different outcomes was calculated according to each specific dalbavancin off-label indication.

Dalbavancin exhibits peculiar PK/PD properties, consisting in a long terminal half-life (approximately 14.4 days), high binding protein (93%), a predominant non-renal clearance, good tissue penetration, and high susceptibility rate (respectively 99.6% and 100.0%) against methicillinresistant Staphylococcus aureus (MRSA) and methicillinsusceptible Staphylococcus aureus (MSSA) isolates according to EUCAST clinical breakpoint (namely 0.125 mg/l). [12] [13] [14] [15] The clearance of dalbavancin was not affected by the presence of cytochrome P450 substrates, cytochrome P450 inhibitors, cytochrome P450 inducers, or selected concomitant medications. Furthermore, age, gender and race had no impact on the pharmacokinetic profile of dalbavancin. 16 The ratio between the mean free-area under the curve and minimum inhibitory concentration (fAUC/MIC) represents the PK/PD parameter best correlating with in vivo efficacy of dalbavancin. 17 The fAUC/ MIC values for net stasis, 1-log kill, and 2-log kill against Staphylococcus aureus were respectively 27.1, 53.3, and 111. 1. 18 No dalbavancin dose adjustment is required in mild-moderate renal impairment, any degree of hepatic impairment, and different modalities of renal replacement therapy (i.e., intermittent haemodialysis, peritoneal dialysis, or continuous renal replacement therapy). [19] [20] [21] Dose reduction should be implemented only in patients affected by severe renal impairment. 19 Dalbavancin exhibits in vitro a potent activity against established biofilms due to Staphylococcus aureus, Staphylococcus epidermidis, and vancomycin-susceptible Enterococci, 22-24 thus possibly playing a crucial role in the management of relevant infections characterized by bacterial biofilm production (e.g., endocarditis, osteomyelitis, device-related infections). Notably, dalbavancin is characterized by good tissue penetration in different sites of infection. Nicolau et al. 25 reported a mean dalbavancin penetration into skin blister fluid of 59.6% after a single 1000 mg infusion, resulting in tissue concentrations well above the MIC 90 of common gram-positive pathogens implicated in ABSSSIs (including MRSA) for up to 7 days. In a phase I study including 35 healthy subjects receiving a single infusion of 1500 mg dalbavancin, Rappo et al. found a penetration into the epithelial lining fluid of 36%, resulting in dalbavancin lung concentrations exceeding the MIC 90 of Streptococcus pneumoniae and Staphylococcus aureus for at least 7 days. 26 Notably, Dunne et al. 2 found a mean bone/plasma AUC of 13.1%, suggesting that two-doses dalbavancin 1500 mg infusion administered one week apart may provide tissue exposure over the MIC for Staphylococcus aureus for 8 weeks. These findings were recently confirmed in a population PK study including 15 patients affected by osteoarticular infections, in which a two 1500 mg dosing regimen of dalbavancin one week apart may ensure efficacy against both MSSA and MRSA for up to 5 weeks. 27 Consequently, these unique PK/PD properties make dalbavancin a valuable alternative to daily in-hospital intravenous or outpatient antimicrobial regimens in the treatment of long-term Gram-positive infections, posing the basis for its use beyond approved indications.

Three studies (two RCTs and one retrospective case-control study) [28] [29] [30] investigated efficacy and safety of dalbavancin compared with standard-of-care (SOC) treatment in different off-label settings (Table 1) . Rappo et al. 28 assessed 80 patients affected by osteomyelitis, 70 of whom were randomized to dalbavancin 1500 mg at day 1 and 8 and the other 10 received SOC (including vancomycin followed by linezolid, levofloxacin, or a third-generation cephalosporin). Staphylococcus aureus was the most frequent isolated pathogen. No difference in clinical cure rate between dalbavancin and SOC was found at the end of treatment (at 42 days; 97% vs 88%). The sixmonths and one-year follow-up assessment confirmed these findings (95% vs 88% and 94% vs 88%, respectively). Only one patient in the dalbavancin group required additional antibiotic therapy for relapse. There was no difference between groups in overall rate of drug-related AEs (1.4% vs 0.0%). Raad et al. 29 assessed in a phase II RCT 67 patients affected by catheter-related bloodstream infections (CR-BSIs), 33 of whom were treated with dalbavancin (1000 mg at day 1 followed by 500 mg at day 8) and the other 34 with vancomycin (1 g q12h for 14 days). At 14-day intervals, dalbavancin showed a significantly higher clinical success rate compared with vancomycin (87.0% vs 50.0%; 95% CI 73.2-100.0% vs 31.5-68.5%). No infection relapse was found in dalbavancin group. Furthermore, no difference in safety was reported between the two groups, and dalbavancin reported no serious AE. Veve et al. 30 

Eleven observational studies [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] and five case reports 8, [42] [43] [44] [45] assessed the efficacy and safety of dalbavancin for the treatment of infective endocarditis (IE; Table 2 ). Overall, 148 patients affected by infective endocarditis were treated with dalbavancin, resulting in a clinical success rate of 81.1%. Different dalbavancin regimens in terms of dose and duration were administered. Relapse was reported in up to 14.3% of cases. Only three cases of dalbavancin resistance have been reported. 32, 44, 45 In the DALBACEN cohort study, 31 34 patients affected by IE (15 prosthetic valve IE, 11 native valve IE, and eight cardiac device-related endocarditis) receiving at least one dose of dalbavancin were assessed. Prior antibiotic therapy implementation was reported in 100.0% of cases, with daptomycin (68.6%) being the most frequent agent used. Dalbavancin was administered as a single-dose or loading dose (LD) of 1000-1500 mg followed by 500-1000 mg weekly for up to 10 weeks. Coagulasenegative Staphylococci (CoNS) were the most frequent isolated pathogens. At 1-year, clinical success was documented in 85.3%. No relapse was reported. AEs occurred in 4.8% of patients, although none of these were serious. Interestingly, in all the three cases of IE caused by Enterococcus faecalis a positive clinical outcome was reported. Tobudic et al. 32 

Ten observational studies, one case series, and six case reports 31,33-41,46-52 assessed the efficacy and safety of dalbavancin for the treatment of bloodstream infections (BSIs) and vascular infections (Table 3) . Overall, 144 patients affected by BSIs or vascular infections were treated with dalbavancin, resulting in a clinical success of 81.3%. Different dalbavancin regimens in terms of dose and duration were administered. In a case of prosthetic graft infection due to Enterococcus faecium, dalbavancin was successfully administered as long-term suppressive therapy for a total of 62 weeks. 40 Overall, relapse was reported in 3.5% of cases. The development of resistance to dalbavancin has emerged in only one case. 49 In the DALBACEN cohort study, 31 

Bone and joint infections represent the most frequent dalbavancin off-label indication. Specifically, one RCT, 28 12 observational studies, 33 

The favourable PK/PD properties of dalbavancin resulting in a single weekly administration and abbreviated dosing schedule may allow for the treatment of endocarditis, osteomyelitis, and vascular infections in an outpatient setting, thus leading to shorter length of hospital stay, reduction in cost and healthcare resource use, and improvement in patient satisfaction. Although different studies 37, [71] [72] [73] [74] [75] [76] assessed the advantages of dalbavancin from a pharmacoeconomic point of view, the consequent impact on quality of life has been less investigated. Early discharge and shorter hospital stays are associated with improved patient quality of life, mobility, and the prevention of non-infectious and infectious catheter-related complications. 8 In the ENHANCE pre-post trial, 77 .001]) in 43 patients treated with dalbavancin for acute bacterial skin and skin structure infections (ABSSSIs) in the post-period compared with 48 subjects receiving usual care in the pre-period. Furthermore, a trend to significant improvement in quality-of-life outcomes was reported with dalbavancin (p = 0.07). However, no difference in absenteeism between pre-and post-period was found. In a post-hoc analysis 78 of a phase 3 RCT involving 698 adult patients with ABSSSIs and treated with dalbavancin (386 and 312 respectively managed in outpatient and inpatient settings), outpatients reported significantly greater convenience and satisfaction with antibiotic treatment and care setting than inpatients. Specifically, a greater number of outpatients versus inpatients reported that antibiotic treatment did not interfere at all with daily activities (74% vs 42%; p<0.001) and that they were easily able to modify their schedule to receive antibiotic therapy (97% vs 76%; p<0.001).

Dalbavancin exhibited an excellent safety profile both in RCTs and observational studies investigating in-and offlabel indications. 79 Dunne et al. 80 performed a pooled analysis of 3002 patients enrolled in seven phase II/III RCTs receiving dalbavancin (N = 1778) or comparators (N = 1224), including vancomycin, linezolid, nafcillin, oxacillin, and cephalosporins. Patients treated with dalbavancin experienced a significantly lower number of overall 81 The excellent safety profile was also confirmed in reallife studies evaluating dalbavancin use in off-label settings (e.g., endocarditis, BSIs, osteomyelitis, joint infections), in which the overall proportion of AEs ranged from 0% to 13%. [28] [29] [30] [31] [32] [33] [34] [36] [37] [38] 40, 41, 54 Furthermore, most AEs were not serious, with serious AEs ranging between 0.0% and 2.9%. [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] 40, 41, 54 Notably, Veve et al. 30 found a significantly lower proportion of AEs in patients treated with dalbavancin for off-label indications (namely osteoarticular infections, IE, and BSIs) compared with vancomycin or daptomycin (3% vs 14%; p = 0.013). Dalbavancin was well-tolerated by children ranging in age from 3 months to 17 years. 82, 83 Additionally, Dunne et al. found no QTc interval prolongation with dalbavancin administration at a dosage up to 1500 mg in healthy volunteers. 84 Finally, Mahoney et al. 85 reported no short-term or long-term AEs in a case of unintentional receipt of 3000 mg of dalbavancin within 20 hours, with the possible exception of mild diarrhoea.

In the last five years, several reports assessing the use of dalbavancin in challenging off-label clinical scenarios have emerged, highlighting the innovative role of this agent for the management of Gram-positive infections usually requiring long-term therapy. Overall, in the 800 identified patients receiving dalbavancin for off-label indications, a positive clinical outcome was reported in a remarkable proportion of subjects, namely in 84.3% of bone and joint infections, 81.3% of BSIs (mainly CR-BSIs or endovascular infections), 81.1% of IE, and 92.0% of other indications (including deep sternal wound infections associated with mediastinitis, intra-abdominal infections, pneumonia, pyelonephritis, and sinusitis; Table 6 ). Notably, in these settings dalbavancin showed a significantly higher clinical cure rate and lower infectionrelated readmission with respect to comparators (namely vancomycin and daptomycin). Furthermore, the occurrence of relapse was limited (below 10%), while resistance development to dalbavancin was reported in only four patients (three cases of infection caused by MRSA and one due to MSSA). Similarly, the emergence of serious safety issues with dalbavancin was negligible.

Notably, the use of dalbavancin in these challenging scenarios exhibits some relevant advantages, specifically allowing for avoiding daily in-hospital intravenous antibiotic treatment or complications associated with outpatient antimicrobial therapy. Indeed, the unique PK/PD properties of dalbavancin resulting in a single weekly administration and abbreviated dosing schedule may allow for the treatment of Gram-positive infections in an Table 6 Cumulative Efficacy Reported with the Use of Dalbavancin for off-Label Therapeutic Indications

Clinical Success Relapse Resistance Development outpatient setting. This represents a crucial aspect in view of the current COVID-19 era, in which patients requiring prolonged (e.g., IE or bone and joint infections) or longterm suppressive (endovascular infections) antibiotic therapy after hospital discharge due to severe Gram-positive infections are at increased risk for contracting and/or transmitting COVID-19 due to extensive contact with the healthcare system. Furthermore, dalbavancin allows a limited healthcare resource use coupled with a lower length of hospital stay, resulting in non-negligible cost savings. In this scenario, dalbavancin could play a key role in enhancing outpatient treatment of several infections requiring long-term antibiotic therapy. Real-world evidence showed a wide heterogeneity in dalbavancin dosing schedule and treatment duration in the different clinical scenarios. Consequently, an attempt to standardize the therapeutic approach in patients requiring dalbavancin for the management of IE, BSI, or bone and joint infections could be made (Figure 1) . A single infusion of 1500 mg, or 1500 mg followed by a second dose of 1000-1500 mg one-week apart could be proposed as the dalbavancin dosing schedule in patients affected by IE. In subjects with prosthetic IE not eligible for surgical treatment or affected by cardiac device-related endocarditis requiring long-term chronic suppression therapy, onceweekly or twice-weekly infusion of dalbavancin 500-1500 mg could be suggested. A single infusion of dalbavancin 1500 mg could be adequate for the treatment of complicated BSI, as well as in the case of CR-BSI. In patients affected by BSI due to prosthetic graft infection or other intravascular source (e.g., left ventricular assistance device infection), a long-term suppression therapy consisting in onceweekly or twice-weekly infusion of dalbavancin 500-1500 mg could be suggested. Dalbavancin dosing schedule proposed by Dunne et al. 2 (1500 mg followed by a second infusion of 1500 mg one-week apart) could be proposed in patients affected by bone and joint infections, considering that this regimen ensures great efficacy against Staphylococcus aureus for up to 5 weeks. In the fifth week, a clinical assessment may allow for considering the administration of an additional dose for prolonging effective treatment. 27 In this case, a therapeutic drug monitoringguided approach could also be implemented to assess the achievement of optimal dalbavancin PK/PD target. The role of dalbavancin combination therapy in off-label indications remains an unmet clinical need. Several in vitro studies showed the synergistic effect of dalbavancin in combination with ceftaroline, cefazolin, daptomycin, rifampicin, and linezolid in reducing the MIC for MRSA, daptomycin non-susceptible, and heterogeneous VISA strains. [86] [87] [88] [89] However, real-world experiences are limited to a single case report of dalbavancin and linezolid combination therapy for the management of a prosthetic joint infection. 60

Dalbavancin shows remarkable efficacy and good tolerability in different challenging scenarios, emerging as a promising alternative in the management of IE, complicated BSI, and osteoarticular infections. The role of dalbavancin is further enhanced in the current COVID-19 era, in which ineluctable hospitalization and empowerment of territorial medicine are strongly required. Further studies assessing the best dosing schedule and the role of combination therapy in each specific scenario are warranted.

Drug Design

The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives

Extended-duration dosing and distribution of dalbavancin into bone and articular tissue

Once-weekly dalbavancin versus daily conventional therapy for skin infection

A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection

Treatment options for carbapenem-resistant gram-negative bacterial infections

Treatment of osteoarticular, cardiovascular, intravascular-catheterrelated and other complicated infections with dalbavancin and oritavancin: a systematic review

Enterococcus faecalis endocarditis and outpatient treatment: a systematic review of current alternatives

Current trends in the real-life use of dalbavancin: report of a study panel

Systemic antibiotic therapy for chronic osteomyelitis in adults

A review of current treatment strategies for infective endocarditis

Outpatient parenteral antimicrobial therapy in the time of COVID-19: the urgent need for better insurance coverage

Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic

Dalbavancin population pharmacokinetic modeling and target attainment analysis

Spectrum and potency of dalbavancin tested against 3322 Grampositive cocci isolated in the United States surveillance program

Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016)

Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide

Drug Design

In vivo pharmacodynamic activity of the glycopeptide dalbavancin

Impact of glycopeptide resistance in staphylococcus aureus on the dalbavancin in vivo pharmacodynamic target

Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment

Intravenous and intraperitoneal pharmacokinetics of dalbavancin in peritoneal dialysis patients

Therapeutic drug monitoring of dalbavancin treatment in severe necrotizing fasciitis in 3 critically ill patients: a grand round

In vitro time-kill kinetics of dalbavancin against Staphylococcus spp. biofilms over prolonged exposure times

In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infections

Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci

Pharmacokinetics of dalbavancin in plasma and skin blister fluid

Epithelial lining fluid and plasma concentrations of dalbavancin in healthy adults after a single 1500-milligram infusion

Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections

Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety

Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens

Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections

DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci

Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the general hospital of vienna

Multicenter clinical experience of real life Dalbavancin use in gram-positive infections

Dalbavancin as secondary therapy for serious staphylococcus aureus infections in a vulnerable patient population

Use of a standardized dalbavancin approach to facilitate earlier hospital discharge for vulnerable patients receiving prolonged inpatient antibiotic therapy

Dalbavancin in the treatment of different gram-positive infections: a real-life experience

Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study)

Dalbavancin in the treatment of bacteremia and endocarditis in people with barriers to standard care

Dalbavancin is a novel antimicrobial against Gram-positive pathogens: clinical experience beyond labelled indications

Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive gram-positive infections

Serum bactericidal activity levels monitor to guide intravenous dalbavancin chronic suppressive therapy of inoperable staphylococcal prosthetic valve endocarditis: a case report

Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: a case report

Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin

Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis

Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source-a series of four cases

Successful treatment of Enterococcus faecalis bacteremia with dalbavancin as an outpatient in an intravenous drug user

Treatment of methicillin-sensitive Staphylococcus aureus bacteremia secondary to septic phlebitis using dalbavancin

Emergence of dalbavancin nonsusceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin-and vancomycin-containing regimen

Dalbavancin as a second-line treatment in methicillin-resistant Staphylococcus aureus prosthetic vascular graft infection

Left ventricular assist device infections and the potential role for dalbavancin: a case report

Treatment with dalbavancin in a patient with septic thrombophlebitis of the internal jugular vein due to Staphylococcus aureus after insertion of an implantable cardioverter defibrillator

Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection

Safety and efficacy of prolonged use of dalbavancin in bone and joint infections

Dalbavancin for the management of gram-positive osteomyelitis: effectiveness and potential utility

Dalbavancin versus standard of care for the treatment of osteomyelitis in adults: a retrospective matched cohort study

Dalbavancin for treating prosthetic joint infections caused by Grampositive bacteria: a proposal for a low dose strategy. A retrospective cohort study

Dalbavancin to treat infected massive endoprostheses: a case report and cost comparison analysis

Successful treatment of diabetic foot osteomyelitis with dalbavancin

Dalbavancin combined with linezolid in prosthetic-hip infection

Experiencia clínica sobre un caso de osteomielitis tratado con dalbavancina

Multiple weekly dalbavancin dosing for the treatment of native vertebral osteomyelitis caused by methicillin-resistant staphylococcus aureus: a case report

Septic arthritis in a native knee due to Corynebacterium striatum

Tratamiento prolongado con dalbavancina en infección protésica de cadera por Staphylocuccus epidermidis resistente a meticilina [Prolonged treatment with dalbavancin in prosthetic hip infection by methicillin

Suppressive antibiotic treatment with dalbavancin. A case report

Dalbavancin treatment of prosthetic knee infection due to oxacillin-resistant Staphylococcus epidermidis

Dalbavancin treatment of methicillin-susceptible Staphylococcus aureus pyomyositis with torpid evolution: a case report

Clinical experience with dalbavancin for the treatment of deep sternal wound infection

Dalbavancin use for the treatment of methicillin-resistant Staphylococcus aureus pneumonia

Dalbavancin treatment in a deep sternal wound MRSA infection after coronary artery bypass surgery: a case report

Dalbavancin use in an academic medical centre and associated cost savings

Stewarding the costly antibiotic: considerations for dalbavancin

Dalbavancin efficacy and impact on hospital length-of-stay and treatment costs in different gram-positive bacterial infections

Potential savings through single-dose intravenous Dalbavancin in long-term MRSA infection treatment -a health economic analysis using German DRG data

Long-acting lipoglycopeptides: "lineless antibiotics" for serious infections in persons who use drugs

Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis

Dalbavancin reduces hospital stay and improves productivity for patients with acute bacterial skin and skin structure infections: the ENHANCE trial

Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections

Review: a safety profile of dalbavancin for on-and off-label utilization

Safety of dalbavancin in the treatment of skin and skin structure infections: a pooled analysis of randomized, comparative studies

Efficacy and safety of dalbavancin in the treatment of Gram-positive bacterial infections

Pharmacokinetics, safety and tolerability of single dose dalbavancin in children 12-17 years of age

Drug Design

Dalbavancin pharmacokinetics and safety in children 3 months to 11 years of age

A thorough QT study with dalbavancin: a novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infections

Receipt of supratherapeutic dalbavancin

Dalbavancin, vancomycin and daptomycin alone and in combination with cefazolin against resistant phenotypes of Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model

Dalbavancin alone and in combination with ceftaroline against four different phenotypes of Staphylococcus aureus in a simulated pharmacodynamic/pharmacokinetic model

In vitro activity of daptomycin combined with dalbavancin and linezolid, and dalbavancin with linezolid against MRSA strains

Activity of dalbavancin, alone and in combination with rifampicin, against meticillinresistant Staphylococcus aureus in a foreign-body infection model

Drug Design, Development and Therapy

Drug Design, Development and Therapy is an international, peerreviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system

This work was supported by an unrestricted grant from Angelini S.P.A.

Dr M Gatti reports grants from Angelini S.p.A., during the conduct of the study. Prof. M Andreoni has participated in advisory boards and/or received speaker honoraria from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme, ViiV Healthcare and has received study grants from Merck Sharp & Dohme, outside the submitted work. Prof. F Pea reports personal fees from Angelini, during the conduct of the study; personal fees from Angelini, Basilea Pharmaceutica, Gilead, Hikma, MSD, Pfizer, Sanofi-Aventis, Shionogi, Thermo Fisher, and Accelerate Diagnostics, outside the submitted work; has participated in speaker's bureau for Accelerate Diagnostics, Angelini, Basilea Pharmaceutica, Gilead, Hikma, MSD, Pfizer, Sanofi-Aventis, Shionogi, Thermo Fisher, and as consultant for Angelini, Basilea Pharmaceutica, Gilead, MSD, Pfizer, Shionogi, outside the submitted work. Prof P Viale has served as a consultant for bioMérieux, Gilead, Merck Sharp & Dohme, Nabriva, Nordic Pharma, Pfizer, Thermo-Fisher, and Venatorx, and received payment for serving on the speaker's bureaus for Correvio, Gilead, Merck Sharp & Dohme, Nordic Pharma, and Pfizer, outside the submitted work. The authors report no other potential conflicts of interest for this work.